Madopar® HBS 125 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02778594 (ClinicalTrials.gov)	September 2005	18/5/2016	Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide	Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers	Parkinson's Disease (PD)	Drug: BIA 3-202;Drug: Placebo;Drug: levodopa 100 mg / benserazide 25 mg	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	Both	17	Phase 1	Portugal
2	NCT03091543 (ClinicalTrials.gov)	May 4, 2004	21/3/2017	Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics	A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg	Parkinson Disease	Drug: Madopar® HBS 125;Drug: Placebo;Drug: BIA 6-512 25 mg dose;Drug: BIA 6-512 50 mg dose;Drug: BIA 6-512 100 mg dose;Drug: BIA 6-512 200 mg dose	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	20	Phase 1	Portugal